Speaker illustration

Mr Gabriel Rubio

Ferrer Internacional, Barcelona (Spain)

Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control

Event: ESC Preventive Cardiology 2021

Topic: Health Economics

Session: Rapid fire abstracts - Secondary Prevention and Rehabilitation


ESC 365 is supported by

logo Novo Nordisk